Singapore, February 5, 2024 – Update on the Detection of the latest SARS-CoV-2 Variant
Credo Diagnostics Biomedical Pte. Ltd. is committed to the post-market monitoring of the reliability of our assays. We have performed nucleotide analysis using the BLASTn method, comparing primers and probes of the assays involving SARS-CoV-2 virus detection to all sequences listed in GISAID until February 5th, 2024.
We are pleased to announce that the VitaPCR™ system is capable of detecting the variant EG.5 and its sublineages HV.1, EG.5.1, and HK.3, and our analysis has confirmed that the performance of our SARS-CoV-2 RNA detection assays* is not impacted by the variant EG.5 and its sublineages HV.1, EG.5.1, and HK.3.
*The SARS-CoV-2 RNA detection assays include:
- VitaPCR™ Influenza/SARS-CoV-2 (Flu/SC2) Assay (PCRAE0128)
- VitaPCR™ SARS-CoV-2 Assay (PCRAE0114)
- VitaPCR™ SARS-CoV-2 Gen 2 Assay (PCRAE0120)
For more information, contact us at service@credodxbiomed.com.
